Panther Fusion® GBS Assay: Testing the Benefits of NAATs versus Culture for Group B Strep Screening
Group B streptococcus (GBS) bacteria is naturally found in around 1 in 4 pregnant patients in the US, and can cause severe infections in newborns when transferred during delivery.1 While updated screening guidelines have dramatically reduced the rates of transmission to newborns, infection remains a public health concern that may demonstrate the need for more accurate […]
Hologic’s AI-Driven Breast Cancer Screening Technology Earns MedTech Breakthrough Award
Next-generation Genius AI® Detection PRO mammography solution delivers new features and can improve diagnostic accuracy by acting as a second set of eyes for radiologists, reviewing cases and flagging potential cancers. MARLBOROUGH, Mass., May 8, 2025 — Hologic, Inc. (Nasdaq: HOLX) today announced that its Genius AI Detection PRO solution has been named “Best New […]
Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients
Completed assessment of more than 2,800 patients highlights the profound impact of the test in helping to predict the likelihood of extended endocrine therapy benefit for patients with HR+ breast cancer to support more informed care decisions MARLBOROUGH, Mass., May 22, 2025 – Hologic, Inc. (Nasdaq: HOLX) and its subsidiary Biotheranostics, Inc., today announced new […]
Hologic Announces Financial Results for Third Quarter of Fiscal 2025
– Revenue of $1,023.8 Million Exceeds Guidance – – Company Reports GAAP Diluted EPS of $0.86; Non-GAAP Diluted EPS of $1.08 Exceeds Guidance – – In Fourth Quarter, Company Remains on Track for Solid Revenue Growth and Faster Non-GAAP EPS Growth – MARLBOROUGH, Mass.–(BUSINESS WIRE)– Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for […]